The chemical class known as T2R29 activators encompasses a diverse range of compounds that can engage and modulate the signaling pathways of the T2R29 bitter taste receptor, which belongs to the family of G protein-coupled receptors (GPCRs). These activators interact with the intricate network of intracellular signaling cascades typically initiated upon ligand binding to T2R29. The primary mechanism through which these activators exert their influence involves either an increase in the concentration of intracellular second messengers such as cyclic adenosine monophosphate (cAMP) and calcium ions or alterations in the activity of enzymes and proteins that are critical components of the signaling pathways associated with T2R29.
For instance, some activators work by directly stimulating adenylyl cyclase, the enzyme responsible for the synthesis of cAMP from ATP, thereby elevating intracellular levels of this secondary messenger and promoting the activation of downstream components that can influence the activity of T2R29. Other compounds in this class function as inhibitors of phosphodiesterases, leading to an accumulation of cAMP within the cell due to reduced breakdown. Moreover, certain activators can alter intracellular calcium concentrations by disrupting the function of specific pumps or channels, thus affecting calcium-dependent signaling processes. Additionally, some molecules target G protein subunits directly or modulate the activity of kinases and phosphatases that are pivotal in GPCR signaling. Collectively, these activators demonstrate the capacity to modulate the T2R29 receptor signaling, affecting the receptor's activity state through a variety of intracellular mechanisms.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
Non-specific inhibitor of phosphodiesterases, increases cAMP by preventing its breakdown, which could possibly activate T2R29. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Induces a sustained increase in cytosolic calcium levels by inhibiting SERCA pumps, which could possibly activate T2R29. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $78.00 $270.00 | 80 | |
A calcium ionophore, increases intracellular calcium concentration, which could possibly activate T2R29. | ||||||
Pertussis Toxin (islet-activating protein) | 70323-44-3 | sc-200837 | 50 µg | $451.00 | 3 | |
Inactivates Gi/o type G-proteins, leading to alterations in GPCR-mediated signaling which could possibly activate T2R29. | ||||||
Chelerythrine chloride | 3895-92-9 | sc-3547 sc-3547A | 5 mg 25 mg | $90.00 $317.00 | 17 | |
A potent inhibitor of protein kinase C (PKC), which is involved in downstream signaling of GPCRs, possibly activating T2R29. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $45.00 $164.00 $200.00 $402.00 $575.00 $981.00 $2031.00 | 46 | |
Inhibits tyrosine kinases which are involved in various signaling pathways, and could possibly activate T2R29. | ||||||
KN-93 | 139298-40-1 | sc-202199 | 1 mg | $182.00 | 25 | |
Inhibits Ca2+/calmodulin-dependent protein kinase II, potentially affecting calcium signaling pathways, which could possibly activate T2R29. | ||||||
BAPTA/AM | 126150-97-8 | sc-202488 sc-202488A | 25 mg 100 mg | $138.00 $458.00 | 61 | |
A cell-permeable calcium chelator that can modulate intracellular calcium levels, which could possibly activate T2R29. | ||||||
Gö 6983 | 133053-19-7 | sc-203432 sc-203432A sc-203432B | 1 mg 5 mg 10 mg | $105.00 $299.00 $474.00 | 15 | |
An inhibitor of PKC, can influence signaling pathways downstream of GPCRs, which could possibly activate T2R29. | ||||||